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ABSTRACT:  
Background: Chronic kidney disease (CKD) results in a dramatic increase in skeletal 
fracture risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but 
they are not recommended in advanced CKD. We have recently shown higher acute skeletal 
accumulation of fluorescently-tagged zoledronate (ZOL) in the setting of CKD but how this 
accumulation is retained/lost over time is unclear. Furthermore, it is unknown if alternative 
dosing approaches can modulate accumulation in the setting of CKD. Methods: To address 
these two questions normal (NL) and Cy/+ (CKD) rats were divided into control groups (no 
dosing), a single dose of a fluorescent-tagged ZOL (FAM-ZOL), a single dose of non-
labelled zoledronate (ZOL) or ten weekly doses of FAM-ZOL each at 1/10th the dose of the 
single dose group. Half of the CKD animals in each group were provided water with 3% 
calcium in drinking water (CKD+Ca) to suppress PTH and remodeling. At 30 or 35 weeks of 
age, serum, tibia, ulna, radius, vertebra, femora, and mandible were collected and subjected 
to assessment methods including biochemistry, dynamic histomorphometry and multi-
spectral fluorescence levels (using IVIS SpectrumCT). Results: FAM-ZOL did not 
significantly reduce bone remodeling in either NL or CKD animals while Ca supplementation 
in CKD produced remodeling levels comparable to NL. At five- and ten-weeks post-dosing, 
both CKD and CKD+Ca groups had higher levels of FAM-ZOL in most, but not all, skeletal 
sites compared to NL with no difference between the two CKD groups suggesting that the 
rate of remodeling did not affect skeletal retention of FAM-ZOL. Fractionating the FAM-ZOL 
into ten weekly doses led to 20-32% less (p<0.05) accumulation/retention of compound in 
the vertebra, radius, and ulna compared to administration as a single dose. Conclusions: 
The rate of bone turnover does not have significant effects on levels of FAM-ZOL 
accumulation/retention in animals with CKD. A lower dose/more frequent administration 
paradigm results in lower levels of accumulation/retention over time. These data provide 
information that could better inform the use of bisphosphonates in the setting of CKD in 
order to combat the dramatic increase in fracture risk.   
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INTRODUCTION:  
 
Chronic kidney disease (CKD) is characterized not only by altered kidney function, but also 
by dramatic alterations in bone and mineral metabolism contributing to the systemic disease 
known as chronic kidney disease-mineral bone disorder (CKD-MBD) [1,2]. Currently, one in 
ten Americans suffer from CKD and the healthcare burden associated with CKD is only 
expected to rise [3]. As kidney function declines, many system functions are affected 
including altered metabolic regulation of mineral metabolism which drives 
hyperparathyroidism and hyperphosphatemia [2]. These changes have established effects 
on the skeleton resulting in the deterioration of skeletal properties primarily in the cortical 
compartment with elevations in cortical porosity. Ultimately, this leads to a striking increase 
in fracture risk and fracture-related mortality among CKD patients [4–8]. 
Treatments for renal osteodystrophy are currently limited. The most common 
therapeutic agent used in other bone loss-related diseases, such as post-menopausal 
osteoporosis, are bisphosphonates, a class of anti-remodeling agents that inhibit osteoclast 
bone resorption. Bisphosphonates are an effective treatment for osteoporosis with a 
reduction in fracture risk and increase in bone mass [9,10]. Bisphosphonate use in early-
stage CKD (stages 1-3) is an acceptable method of treatment according to 
recommendations by the Kidney Disease Improving Global Outcomes committee (KDIGO); 
yet their use in later stage CKD (stages 3 – 5) is discouraged when patients have evidence 
of biochemical abnormalities, such as secondary hyperparathyroidism, typical of CKD-MBD 
[1,11]. The concern for use of bisphosphonates among renally impaired patients come from 
studies utilizing rapid infusion rates and high peak concentrations of bisphosphonates 
(zoledronate and pamidronate) typical of preventive or therapeutic treatment of bone 
metastases, resulting in evidence of nephrotoxicity [12,13]. In addition to nephrotoxicity, 
there are concerns that bisphosphonates may accumulate in excess in the skeleton due to 
their dependence on the kidney to be cleared. Therefore, severe CKD cases might lead to 
drug overexposure and over suppression of remodeling within the skeleton in CKD patients 
compared to individuals with normal kidney function  [14–16]. Recent work from our lab 
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supports this concern, as rats with CKD displayed significantly higher accumulation within 
the skeleton after an acute dose of fluorescently-labelled zoledronate [17]. However, there is 
still an absence of data assessing the impact of skeletal bisphosphonate accumulation over 
time in conditions of varying turnover rates and with different dosing regimens [18]. 
 The goal of this study was to measure fluorescently-tagged zoledronate 
accumulation and retention within the skeleton in a rodent model of progressive chronic 
kidney disease. We hypothesized that reduced kidney function would result in higher skeletal 
accumulation of bisphosphonates. We also hypothesized that skeletal accumulation of 
bisphosphonates would be modulated by both the frequency of bisphosphonate dosing and 
bone turnover levels.  
 
METHODS:  
 
Animals. The male Cy/+ Han:SPRD rat (referred to as CKD hereafter) derived from the 
colony maintained at Indiana University School of Medicine, represents an animal model of 
spontaneous and slowly progressing kidney disease [2]. Our previous work has shown 
evidence of 50% reduction in kidney function at ~20-25 weeks of age compared to normal 
littermates (NL) [2]. As animals age, the kidney disease progresses to the point of about 10-
15% kidney function by 35 weeks. Throughout this time CKD-MBD characteristics develop 
with prominent hyperphosphatemia, hyperparathyroidism, vascular calcification, and skeletal 
deterioration [2,19–23]. 
  
 
Experimental Design. All procedures conducted during this study were reviewed and 
approved by the Indiana University School of Medicine Institutional Animal Care and Use 
Committee. Animals were given group designation (NL or CKD) at 10 weeks of age based 
on blood urea nitrogen (BUN, > 30mg/dL designated as CKD). At 24 weeks of age, all 
animals began a casein-based diet (Harlan Teklad TD.04539), a method that has been 
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shown to produce a more consistent model of CKD progression [2]. Animals were used in 
one of two different experiments (Figure 1). 
Experiment 1 - 30 weeks 
At 25-weeks of age, NL (n = 18) and CKD animals (n = 18) were randomly divided (within 
genotype) into six groups (n=6 animals each):  
NL - control group (no dosing) 
NL - a single subcutaneous (SQ) 180 µg/kg dose of a fluorescent-tagged ZOL (FAM-
ZOL) at 25 weeks of age. 
NL - a single dose of 100 µg/kg non-labelled zoledronate (ZOL) at 25 weeks of age 
CKD - control group (no zoledronic acid dosing) 
CKD - a single SQ 180 µg/kg dose of a fluorescent-tagged ZOL (FAM-ZOL) at 25 
weeks of age 
CKD - a single SQ 180 µg/kg dose of a fluorescent-tagged ZOL (FAM-ZOL) at 25 
weeks of age with 3% calcium gluconate in drinking water (starting at 24 
weeks of age (7 days before FAM-ZOL dose) and continuing throughout 
the experiment)) to suppress bone remodeling throughout the study 
[21,24]. 
 
This FAM-ZOL has been previously used in our work and others to allow for 
assessment of accumulation within the bone [17,25]. In order to evaluate the remodeling 
suppression activity of FAM-ZOL animals were administered a single subcutaneous dose 
(180 µg/kg). The manufacture data sheet recommends dosing at 50-100 nmol/kg, yet based 
on the discussions with the manufacturer a dose of 255 nmol/kg (180 ug/kg) may be 
necessary for remodeling suppression. Thus, this dose was chosen for the current work. A 
group of NL animals were administered a subcutaneous single dose of non-labelled 
zoledronic acid (ZOL; 100µg/kg). This dose of zoledronate has been previously shown to be 
effective in suppressing remodeling [21,24] and although it represents a higher molar 
concentration than FAM-ZOL (367 nmol/kg) we have previously shown a lower dose of ZOL 
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(20 µg/kg; 74 nmol/kg) suppresses remodeling to a similar degree as the higher dose.  
Calcium water supplementation (3% calcium gluconate) was provided ad libitum in order to 
suppresses bone turnover, which occurs in this CKD model to a similar degree as ZOL 
treatment [21, 24].  
All animals were administered a subcutaneous calcein injection (30µg/kg) thirteen 
and six days before the 30-week endpoint enabling the assessment of dynamic bone 
formation. As previously described in our work, calcein blue was used to avoid spectral 
overlap with FAM-ZOL [17,26]. At 30 weeks of age animals were anaesthetized with 
isoflurane before euthanasia by exsanguination. Serum, tibia, ulna, radius, L3 vertebra, 
femora, and mandible were collected. Tissues were stored in 10% NBF for 24 hours before 
switching to 70% EtOH for long term storage [17].  
 
Experiment 2 - 35 weeks  
At 25 weeks of age, NL and CKD animals were divided into the below groups (n=6/gp): 
 NL - control group (no dosing) 
NL - a single subcutaneous (SQ) 180 µg/kg dose of a fluorescent-tagged ZOL (FAM- 
ZOL) at 25 weeks of age 
 NL - weekly SQ doses of 18 µg/kg FAM-ZOL starting at 25 weeks of age 
 CKD - control group (no dosing) 
 CKD - a single SQ 180 µg/kg dose of FAM-ZOL at 25 weeks of age 
 CKD - weekly SQ doses of 18 µg/kg FAM-ZOL starting at 25 weeks of age 
 CKD - a single SQ 180 µg/kg dose of FAM-ZOL and supplemental with 3% calcium  
gluconate in drinking water (starting at 24 weeks of age (7 days before FAM-
ZOL dose) and continuing throughout the experiment)). 
 CKD - weekly SQ doses of 18 µg/kg FAM-ZOL and supplemental with 3% calcium  
gluconate in drinking water (starting at 24 weeks of age (7 days before FAM-
ZOL dose) and continuing throughout the experiment)). 
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The animals who received a single dose of FAM-ZOL were administered a single 
dose of FAM-ZOL subcutaneously (180 µg/kg) at 25 weeks of age. Similar to experiment 1, 
3% calcium gluconate was supplemented to drinking water in select groups to create a low 
turnover CKD model [21, 24]. Calcium water supplementation started at 24 weeks and 
continued throughout the duration of the study until euthanasia at 35 weeks of age. Some 
animals received ten weekly FAM-ZOL injections at 1/10th of the single FAM-ZOL dose (18 
µg/kg per injection). This dose was arbitrarily determined by diving the total dose equally 
over the experimental period. Parallel to experiment 1, all animals received a subcutaneous 
calcein blue injection (30µg/kg) thirteen and six days before euthanasia and collection of 
tissue at 35 weeks of age.  
 
Biochemistries. Blood (~500µL) was collected from the tail vein at 25-weeks of age, prior to 
treatment, to determine baseline biochemistries. Blood was again measured at experimental 
endpoint (30 or 35 weeks) prior to euthanasia. BUN (BioAssay systems #DIUR-100), 
calcium (Pointe Scientific, #C7503-480), and phosphorus (Pointe Scientific, #P7516-500) 
were analyzed using colorimetric assays. PTH was measured using an ELISA assay 
(Immunotopics). 
 
Multi-Spectral Decomposition (MSD). Mandible, radius, ulna, vertebra (3rd lumbar, L3), 
distal femur, and proximal tibia were assessed for whole bone fluorescence using 
reflectance epi-fluorescence imaging (IVIS SpectralCT, PerkinElmer). Our lab and others 
have previously used this method as an assay to measure fluorescently-tagged 
bisphosphonate levels in tissues [17,25,27,28]. Mandible, radius, and ulna were scanned 
whole whereas, vertebrae processes were removed, and distal femur and proximal tibiae 
were cut to 10 mm standard length sections. For each skeletal site, a bone from each animal 
was run on a single plate to assume uniform scan setting. While this allows comparison 
across animals within bone site, the optimization of settings to accommodate for the size 
differences among bone sites restricts the ability to compare levels across bone sites. 
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Exposure time was approximately one second per sample plate using broad emission 
spectral excitation and emission ranging of 430-465nm and 500-540nm, respectively. FAM-
ZOL signal was distinguished from auto fluorescence and calcein blue signals by spectrally 
unmixing the image series (Living Image, PerkinElmer). In all cases, bone fluorescence 
levels are reported as average radiant efficiency ([photons/second]/[μW/cm2]).  
 
Histology.  L3 vertebra were infiltrated and embedded with methyl methacrylate as 
previously described in our laboratory [29]. Vertebra were sectioned in the parasagittal plane 
for trabecular bone assessment. All slides were cover slipped with a Eukitt, a non-
fluorescent mounting medium (Kindler, Freiburg, Germany). Sections were analyzed for 
dynamic histomorphometry parameters (Bioquant) from images collected by 2-photon 
microscopy with this method being previously described as it enabled the visualization of 
calcein blue [17]. Trabecular dynamics were determined from a region ~0.5mm distal to the 
proximal vertebral growth plate.  Mineral apposition rate (MAR. %), mineralizing surface 
(MS/BS, %) and bone formation rate (BFR/BS, μm3/μm2/year) were calculated using 
standard methods [30].  
 
Statistics 
All analyses were performed using GraphPad software.  For the 30-week experiment, the 
goals were two-fold: first, to assess the effect of remodeling suppression NL, CKD, NL-ZOL, 
NL-FAM-ZOL, CKD-FAM-ZOL and CKD-Ca-FAM-ZOL were compared in a One-Way 
ANOVA. Second, to assess accumulation/retention of FAM-ZOL the three groups receiving 
FAM-ZOL (NL-FAM-ZOL, CKD-FAM-ZOL and CKD-Ca-FAM-ZOL) were compared with one-
way ANOVA. For both tests, if the ANOVA p<0.05, a Tukey post-hoc analysis was 
completed. For the 35 week experiments, primary assessment of FAM-ZOL accumulation 
was determined using One-Way ANOVA on those receiving single doses of compound (NL-
FAM-ZOL, CKD-FAM-ZOL and CKD-Ca-FAM-ZOL).  To assess the role of fractionated 
dosing, a Two-Way ANOVA was used for each skeletal site to study the main effects of 
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condition (normal (NL), low (CKD), high (CKD+Ca)) and dose (single, fractionated) and then 
the interaction between the two. In all cases, statistical significance was determined when a 
priori two tailed p values were ≤ 0.05.  
 
RESULTS 
 
At the 30-week timepoint, 5 weeks after a single dose of FAM-ZOL, there was no 
significant effect on trabecular bone dynamic bone remodeling parameters in either NL or 
CKD groups relative to the non-dosed control (Figure 2, Table 1).  In contrast, a single dose 
of ZOL in NL animals produced a robust suppression of MS/BS, MAR, and BFR compared to 
untreated NL animals. CKD animals supplemented with calcium water also had significantly 
lower bone remodeling compared to CKD controls.  These data demonstrate that FAM-ZOL, 
at this dose, does not suppress remodeling despite robust surface binding [17]. Based on 
this finding, results presented hereafter are considered to provide insight into FAM-ZOL 
accumulation/retention in the setting of high and low turnover (CKD and CKD+Ca, 
respectively). 
 The 30-week experiments (representing five weeks post-dosing) revealed that both 
high and low turnover CKD animals had significantly higher levels of FAM-ZOL in mandible, 
distal femur, and radius compared to NL (Figure 3; Supplementary Table 1). The mandible 
had significantly lower FAM-ZOL levels in CKD+Ca compared to CKD. The L3 was 
significantly higher than NL only in low turnover (CKD+Ca) while the proximal tibia was 
higher only in higher turnover (CKD).   The ulna did not show any significant differences. 
 The 35-week experiments (representing ten weeks post-dosing) revealed a similar 
pattern of results as was quantified at 5 weeks post-dosing (Figure 4; Supplementary 
Table 1).  Proximal tibia, distal femur, and mandible were significantly higher in FAM-ZOL 
accumulation in both high and low turnover CKD animals, relative to NL, with no difference 
between the two CKD groups.  Levels of accumulation in L3 and the radius were significantly 
higher in low turnover CKD (CKD+Ca) relative to NL.  The ulna did not show significant 
differences among groups. 
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 There were significant main effects of dosing regimen (single dose versus 
fractionated dose) in the radius, ulna, and L3 (Figure 5; Table 2).  Those animals receiving 
a fractionated dose had significantly less accumulation/retention of drug, independent of 
treatment. The lone exception to this pattern was at the distal femur where only low turnover 
CKD animals had lower levels of accumulation with the fractionated dose compared to the 
full dose (Figure 5).   
Serum biochemistries, noting presence/absence of kidney disease (assessed by 
BUN) and hyperparathyroidism (assessed by PTH) showed expected results in groups from 
both experiments (Table 3). 
 
Discussion 
This study aimed to characterize the effects of bisphosphonate 
accumulation/retention in the context of progressively advancing chronic kidney disease. Our 
results show that a single dose of fluorescently labeled zoledronate (FAM-ZOL) is retained in 
the skeleton to a greater degree in rats with CKD versus those with normal kidney function 
irrespective of whether there is high or low turnover. Additionally, this study also 
demonstrates that more frequent, smaller doses of FAM-ZOL results in lower skeletal 
accumulation/retention regardless of disease state (NL and CKD) or level of turnover (high 
vs low). Alternative dosing schedules such as this could represent a path forward for dosing 
bisphosphonates in patients where renal safety is of a concern, although additional work on 
bone mechanical properties and renal function would need to be investigated first. 
Zoledronate (ZOL) is a clinically relevant drug commonly used in osteoporosis to 
slow bone loss and reduce fracture risk. With a high affinity binding to hydroxyapatite, 
zoledronate is a potent suppressor of bone turnover, and when unbound to the bone 
surface, it is excreted unmetabolized by the kidneys [21]. Elimination through the kidney has 
raised concern that in the setting of reduced kidney function, higher levels of drug will be 
exposed to the kidney (potentially causing nephrotoxicity) and may also accumulate in the 
skeleton. Our lab has previously shown that the dose of zoledronate used in this study, as 
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well as doses 5x lower, produces a robust reduction in turnover markers (BFR, MAR, and 
MS/BS) and thus we chose to use this specific bisphosphonate, as opposed to the 
numerous others, for the studies described herein [21,24]. Fluorescently labeled zoledronate 
(FAM-ZOL) enabled unique tracking of the compound and our previous work documents that 
this compound retains its high affinity binding properties illustrated by the fact that it covers 
the majority of surfaces (~80-100%) as assessed 24 hours post dosing [17]. 
 In agreement with our previous short-term study of increased FAM-ZOL 
accumulation and retention in CKD animals 24 hours post-dosing [17] these results 
demonstrate that fluorescently-labelled zoledronate levels are significantly higher in animals 
with CKD compared to littermates with normal kidney function irrespective of bone 
remodeling rate (CKD versus CKD+Ca) (Figure 3 and 4). Calcium water supplementation 
was utilized to suppress PTH levels and showed, similar to previous work [21], a robust 
suppression of turnover (Table 1 and Figure 2) that was equivalent to ZOL at 5 weeks post-
treatment. Assessment of accumulation in this low turnover group has clinical implications as 
roughly 20% of patients with stage 3-5 CKD have low bone turnover; this number increases 
to nearly 50% in patients undergoing dialysis [31]. Importantly, we document here that there 
was minimal difference in accumulation between CKD rats with high PTH/high turnover 
(CKD no dosing) and CKD rats with low PTH/low turnover (CKD+Ca) (Figure 3 and 4). 
Important in the interpretation of our results, the initial dosing of FAM-ZOL in the CKD+Ca 
group would have been in a state of high/moderate low turnover due to the administration 
and commencement of calcium water treatment simultaneously. Our previous work has 
shown that at the age of dosing (25 weeks old), CKD animals have 60% higher trabecular 
bone formation rate (BFR) compared to normal. We are unable to know the rapidity with 
which Ca treatment reduces bone formation rate although unpublished data from our lab 
show that by 7 days post Ca treatment, CKD animals have significantly higher trabecular 
BV/TV – a variable that further increases with longer duration Ca treatment.  Thus, within the 
first seven days (the duration prior to BP dosing in the current work) the Ca has begun to 
have a biological effect.  That said, we do not know the remodeling rate of these animals and 
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so cannot know turnover levels at the time of dosing FAM-ZOL. While this could have 
influenced initial binding, the handling of FAM-ZOL would have occurred in a lower turnover 
state which we know exists for the majority of the experiment given the suppression at 30 
weeks.  
FAM-ZOL levels in bone were significantly higher in CKD animals at both 5- and 10-
weeks post injection suggesting that there is long-term retention of the drug is not 
significantly dependent on turnover state (Figure 3 and 4). Although the retention of drug in 
low-remodeling states is intuitive, the retention in high remodeling states seems less so. We 
hypothesize that in the setting of high turnover CKD, some of the FAM-ZOL is liberated from 
the bone but, due to reduced kidney function and high bone affinity, it is recirculated and 
becomes rebound rather than excreted. In support of this, a qualitative analysis of 
histological samples from select high-turnover CKD animals showed secondary bands of 
FAM-ZOL (Supplementary Figure 1). Unfortunately, it was not possible to quantitatively 
differentiate levels of drug that were the result of the original dose versus that which is 
recirculated. 
 CKD rats, irrespective of turnover rate, retain higher levels of FAM-ZOL in the 
skeleton. Although many strategies could be employed to try and reduce accumulation, we 
chose to test the hypothesis that smaller, more frequent doses of FAM-ZOL would lower 
levels within bone. Our rationale for this approach is that, in addition to potentially lowering 
levels in the bone, a more frequent dose would allow a continued ‘resurfacing’ of bone 
surfaces with drug to slow resorption. This portion of the experiment provided clear evidence 
that irrespective of disease state, CKD or NL, the accumulation of FAM-ZOL in bone was 
lower with fractionated dosing (Figure 5). In CKD animals, again bone turnover rate did not 
have significant effects as both high and low turnover animals had lower 
accumulation/retention of FAM-ZOL at multiple skeletal sites when compared to the single 
bolus dose (Figure 5). Similar to the single dose, the early fractionated doses of CKD+Ca 
FAM-ZOL would likely have been administered prior to the effectiveness of Ca to suppress 
turnover yet subsequent fractionated doses, the majority of them, would have been in a low 
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turnover state. Therefore, a greater proportion of the fractionated dose in the CKD+Ca group 
occurred during a lower turnover state compared to the single dose individuals.  
The overall finding demonstrating a lower accumulation/retention when fractionating 
the bisphosphonate dose into more frequent and lower doses is beneficial for rethinking the 
paradigm for studying bisphosphonates in CKD patients. We speculate that smaller doses of 
bisphosphonates permit a greater initial clearance of bisphosphonate from the kidneys 
before it is able to localize to bone. Potentially more of the bisphosphonate is excreted when 
given in smaller and more frequent doses since the kidneys are able to handle the smaller 
amounts of the drug more efficiently. Alternatively, the lower accumulation in the fractionated 
dose could be explained by the progressive lowering of turnover over time. From a clinical 
standpoint, providing more frequent dosing of zoledronate would seem unrealistic due to its 
IV administration, other bisphosphonates such as alendronate and risedronate, typically 
used in oral form, may be more conducive to dosing on a weekly or even monthly basis. 
How this alternative dosing regimen affects other aspects of the disease, such as the 
progression of skeletal resorption (bone porosity), reduction in mechanical properties, as 
well as kidney function will necessitate additional studies with active bisphosphonate.  
 Data regarding bisphosphonate handling (accumulation/retention) has existed for 
decades and is highlighted by the elegant studies using numerous doses/regimens of 
alendronate in rodents. These studies documented that post-dose binding occurs 
predominantly within the first 6 hours post dose and the skeleton can be saturated for a 
single dose but that fractionating with repeated doses has the potential to lead to higher 
accumulation than single doses. There is a less robust understanding of how splitting a 
single dose into smaller but more frequent administrations (as done here) affects 
accumulation.  Additionally, there is currently no data about drug retention/recycling. In vivo 
bound drug is thought to be released during resorption but then also freely dissociates from 
surfaces.  The relative proportion between these two processes is not clear. This work has 
been undertaken almost exclusively in normal animals and thus the current work advances 
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these findings to a disease model where the main method of drug elimination (kidney) is 
compromised. 
 There are limitations to this study which are important to note. Firstly, FAM-ZOL at 
this dose did not suppress bone turnover compared to zoledronate (Figure 1 and Table 1). 
Despite previous work suggesting in vivo efficacy of FAM-ZOL (based on trabecular BV/TV 
changes), our work utilizing the gold-standard method of dynamic histomorphometry clearly 
shows a lack of effect on bone remodeling as compared to the native zoledronate drug. We 
hypothesize that the addition of a fluorescent adduct to the nitrogen side chain (R2) changes 
FAM-ZOL ability to bind to the active site of the farnesyl diphosphate synthase (FPPS) 
enzyme which is essential in the inhibition of the FPPS pathway and subsequent osteoclast 
inhibition. Since FAM-ZOL compound modifications do not affect the hydroxyl (R1) chain, 
regular bone and mineral binding can still occur as can be clearly noted in the current work. 
The dose of FAM-ZOL, chosen based on the recommendation of the manufacturer, was 
lower on a nmol/kg basis (255 nmol/kg) than ZOL (367 nmol/kg), yet in our previous work we 
have shown that this dose of ZOL (367 nmol/kg; 100 ug/kg) and a lower dose of ZOL (74 
nmol/kg; 20 ug/kg) equally suppressed bone formation rate.  Thus, the lower dose of FAM-
ZOL is unlikely the explanation although we cannot discount that a higher dose of FAM-ZOL 
could have biological activity. 
Despite the lack of effect, we believe the results are still noteworthy as they address 
FAM-ZOL accumulation/retention dynamics in the setting of high and low turnover CKD. 
These studies support and extend our previous short-term retention study findings showing 
that there is a disparity between bisphosphonate handling between CKD and normal 
individuals. Secondly, zoledronate was the only bisphosphonate assessed in this study, 
therefore, the generalizability of results to other bisphosphonates should be approached with 
caution. Furthermore, zoledronate and FAM-ZOL were administered subcutaneously rather 
than IV, as typically done in patients. However, as described previously, IV and SC dosing 
have been shown to exhibit comparable FAM-ZOL accumulation [17]. We can also not 
discount the contribution of the fluorescent conjugation to zoledronate affecting dynamics of 
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accumulation/retention.  Finally, our results assume that the low turnover state that comes 
from Ca water supplementation is similar to that which occurs from an active 
bisphosphonate and this may not be the case. 
  In conclusion we have documented that FAM-ZOL accumulates and is retained at 
significantly higher levels in the setting of CKD compared to normal and that remodeling rate 
is not having a significant effect on accumulation/retention in CKD. Additionally, 
administering FAM-ZOL with more frequent and lower doses appears to be a viable 
mechanism to reduce the level of drug accumulation in the skeleton in both normal and CKD 
settings.  
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TABLES 
 
Table 1. Proximal tibia dynamic histomorphometry data at 5 weeks post dosing. 
 
 NL CKD  
 CON ZOL FAM-
ZOL 
CON FAM-
ZOL 
FAM-ZOL 
+ Ca 
Overall 
ANOVA  
P value 
MAR, 
um/day 
1.02 ± 
0.18 
0.38 ± 
0.43 * 
1.08 ± 
0.17 
1.32 ± 
0.35 
1.38 ± 
0.45 
0.87 ± 
0.26 
< 0.0001 
MS/BS,% 23.7 ± 
4.4 
2.7 ± 
 1.9 * 
24.5 ± 
4.08 
28.5 ± 
9.9 
26.8 ± 
8.7 
16.3 ±  
8.6 
0.0001 
Data presented as mean and standard deviation. NL-normal; CKD-chronic kidney disease; 
CON – no dosing; ZOL – zoledronate; FAM-ZOL – fluorescently-tagged zoledronate; CA – 
calcium. * p < 0.05 vs NL-CON 
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Table 2.  Effects of dose fractionation on skeletal accumulation/retention of FAM-ZOL. 
 
Data presented as mean and standard deviation. All values are reported as: average radiant 
efficiency ([photons/second]/[μW/cm2]). NL-normal; CKD-chronic kidney disease; CA – 
calcium. * p < 0.05 compared to 1 dose within condition. 
 
 
 
 
 
 
  
Condition NL CKD (High Turnover) CKD+Ca (Low Turnover) P value 
Dose 1 dose 10 doses 1 dose 10 doses 1 dose 10 doses Dose Condition Int. 
          
Mandible 75.1 x 10
9
 
±  
20.8 x 10
9
 
60.9 x 10
9
 
±  
17.0 x 10
9
 
153 x 10
9
  
±  
44.4 x 10
9
 
152 x 10
9
  
±  
35.7 x 10
9
 
156 x 10
9
  
±  
41.4 x 10
9
 
114 x 10
9  
±  
28.3 x 10
9
 
0.1014 
 
<0.0001 
 
0.3296 
 
Proximal 
tibia 
8.15 x 10
9
 
±  
4.6 x 10
9
 
6.52 x 10
9
 
±  
3.25 x 10
9
 
16.6 x 10
9
 
±  
5.79 x 10
9
 
15.7 x 10
9
 
±  
5.46 x 10
9
 
18.9 x 10
9
 
±  
2.97 x 10
9
 
14.2 x 10
9
 
±  
5.95 x 10
9
 
0.1551 <0.0001 
 
0.6249 
Ulna 26.1 x 10
9
 
±  
16.5 x 10
9
 
18.4 x 10
9
 
±  
8.36 x 10
9
 
48.4 x 10
9
 
±  
26.7 x 10
9
 
40.0 x 10
9
 
±  
13.3 x 10
9
 
60.8 x 10
9
 
±  
23.4 x 10
9
 
35.8 x 10
9
 
±  
15.0 x 10
9
 
0.0307 
 
0.003 
 
0.4562 
 
Radius 13.2 x 10
9
 
±  
7.45 x 10
9
 
9.87 x 10
9
 
±  
4.09 x 10
9
 
23.3 x 10
9
 
±  
8.18 x 10
9
 
20.8 x 10
9
 
±  
4.61 x 10
9
 
29.3 x 10
9
 
±  
6.59 x 10
9
 
21.2 x 10
9
 
±  
7.08 x 10
9
 
0.0388 
 
<0.0001 
 
0.5479 
 
L3 3.48 x 10
9
 
±  
2.64 x 10
9
 
2.63 x 10
9
 
±  
1.26 x 10
9
 
8.11 x 10
9
 
±  
3.26 x 10
9
 
5.96 x 10
9
 
±  
2.7 x 10
9
 
10.5 x 10
9
 
±  
3.05 x 10
9
 
5.83 x 10
9
 
±  
4.05 x 10
9
 
0.0134 
 
0.0005 
 
0.3082 
 
Distal 
Femur 
7.06 x 10
9
 
±  
4.19 x 10
9
 
6.59 x 10
9
 
±  
2.42 x 10
9
 
16.5 x 10
9
 
±  
5.07 x 10
9
 
15.8 x 10
9
 
±  
2.67 x 10
9
 
20.0 x 10
9
 
±  
2.28 x 10
9
 
12.3 x 10
9
 
±  
3.77 x 10
9
 
* 
0.0182 
 
<0.0001 
 
0.0351 
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Table 3. Body mass and serum biochemistries. 
 
 Normal CKD  
 CON ZOL FAM-
ZOL 
FAM-
ZOL 
FRAX 
CON FAM-
ZOL 
FAM-
ZOL 
FRAX 
CA+FAM-
ZOL 
CA+FAM-
ZOL FRAX 
Overall 
ANOVA  
P value 
30-week experiment 
Body 
mass, 
g 
536 ± 
25 
541 
± 27 
523 ± 
10 
- 561 ± 
22 
554 ± 
30 
- 541 ± 23 - 0.1904 
Final 
BUN, 
mg/dL 
19.1 
± 1.7 
18.2 
± 1.8 
18.4 
± 1.1 
NA 39.7 ± 
6.0* 
37.5 ± 
7.6* 
NA 42.4 ± 4.9* NA <0.0001 
 
FINAL 
PTH, 
pg/ml 
376 ± 
298 
- 379 ± 
256 
NA 420 ± 
379 
475 ± 
230 
NA 195 ± 159 NA 0.4900 
           
35-week experiment 
Body 
mass, 
g 
590 ± 
34 
NA 573 ± 
44 
549 ± 
33 
512 ± 
57 
569 ± 
43 
503 ± 
60 
549 ± 60 487 ± 84 * 0.027 
Final 
BUN, 
mg/dL 
18.1 
± 1.8 
NA 19.8 
± 2.5 
18.9 ± 
1.5 
50.4 ± 
8.0 * 
45.9 ± 
6.5 * 
50.1 ± 
8.0 * 
49 ± 9.4 * 53.7 ± 8.7 * <0.0001 
 
FINAL 
PTH, 
pg/ml 
123 ± 
49 
NA - - 2105 
± 
340* 
1403 ± 
664* 
1266 
± 831* 
33 ± 42 49 ± 45 <0.0001 
 
Data presented as mean and standard deviation. NA – group was not included at that 
timepoint; - data not measured. NL-normal; CKD-chronic kidney disease; CON – no dosing; 
ZOL – zoledronate; FAM-ZOL – fluorescently-tagged zoledronate; CA – calcium. * p < 0.05 
vs Normal CON. 
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Figure Legends 
Figure 1: Experimental design and treatments for experiment 1 (30 weeks) and 2 (35 
weeks).  
Figure 2: Proximal tibia bone formation rate (BFR/BS) by histomorphometry analysis, 5-
weeks post dosing.  Data is presented as the mean and standard deviation with individual 
data points presented. * denotes a significant difference (p<0.05) between NL control and 
NL ZOL. # denotes significance (p<0.05) between CKD control and CKD Ca FAM-ZOL. 
 
Figure 3: Skeletal accumulation of FAM-ZOL displayed as total radiant efficiency at multiple 
skeletal sites 5-weeks after a single dose of FAM-ZOL. Data is presented as means and 
standard deviation with individual data points displayed. * denotes significance (p<0.05) vs. 
normal control based on a one-way ANOVA. 
 
Figure 4: Skeletal accumulation of FAM-ZOL displayed as total radiant efficiency at multiple 
skeletal sites 10-weeks after a single dose of FAM-ZOL. Data is presented as means and 
standard deviation with individual data points displayed. Significance is denoted * p<0.05, ** 
p<0.01, *** p<0.001 vs. normal control based on a one-way ANOVA. 
 
Figure 5: Skeletal accumulation of fractionated FAM-ZOL dosing measured as total radiant 
efficiency by a two-way ANOVA at multiple skeletal sites. Data is presented as means and 
standard deviation. Clear and black bars represent single and fractionated dosing 
respectively. Values for interaction, condition, and disease affects are presented with 
significance determined when p<0.05. * notes a significant difference within condition when 
an interaction term was significant. Percent differences comparing single vs. fractionated 
dosing for each treatment group across all skeletal site are displayed above the paired bar 
graphs.  
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Highlights 
 
-Bisphosphonates effectively preventing bone loss in many conditions but are not used in 
CKD. 
 
-Levels of bisphosphonate accumulation and retention are studied in an animal model of 
CKD. 
 
-More frequent, lower doses of bisphosphonate result in lower overall 
accumulation/retention compared to single doses. 
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